Our partner acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. They have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for their diverse pipeline.

This senior leader was responsible for developing regulatory strategies for small molecules, biologics, and novel therapies for multiple indications. This included the evaluation of regulatory risks/gaps and developing contingency plans for overall early development programs with a focus on efficient global planning for first-in-human and proof-of-concept studies.